Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the acf domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/worldpharmatoday.com/httpdocs/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the filebird domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/worldpharmatoday.com/httpdocs/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the td-cloud-library domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/vhosts/worldpharmatoday.com/httpdocs/wp-includes/functions.php on line 6121
Press Releases - Part 153

Press Releases

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Gilead Sciences, Inc. announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program. JTX-1811 is a monoclonal antibody designed to selectively...

Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, announced the closing of a $16 million Series B financing. The financing was co-led by new investor WestRiver Management and returning investor Bioeconomy Capital, with additional...

Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing...

Promega Launches Spectrum Compact CE Benchtop DNA Analysis Instrument with Hitachi High-Tech

Promega launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech. The personal CE system is an integrated DNA analysis instrument that enables life scientists in laboratories of all sizes to...

Enabling flexible adaption to changing requirements for the packaging of solida and parenteral medicines

Solida and parenteral blister packs are often produced on monobloc machines designed for specific applications. Format changes are complex and expensive procedures. In packaging medication, the pharmaceutical industry must not only meet the highest quality standards, but also increasingly...

AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab (PRV-031) for partner Provention Bio, Inc., a biopharmaceutical company dedicated to...

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the world's first prophylactic vaccine against gonorrhea, NGoXIM. For this Therapyx received...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read